A Single-center, Open Label, Single-dose Study to Investigate the Effect of Severe Renal Impairment on the Pharmacokinetics of ACT-132577
Phase of Trial: Phase I
Latest Information Update: 14 Nov 2017
At a glance
- Drugs Aprocitentan (Primary)
- Indications Cardiovascular disorders; Hypertension
- Focus Pharmacokinetics
- Sponsors Actelion Pharmaceuticals; Idorsia Pharmaceuticals
- 08 Nov 2017 Status changed from recruiting to completed.
- 26 Oct 2017 Planned End Date changed from 29 Sep 2017 to 30 Oct 2017.
- 26 Oct 2017 Planned primary completion date changed from 29 Sep 2017 to 30 Oct 2017.